News headlines about DURECT Corporation (NASDAQ:DRRX) have trended somewhat positive on Friday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. DURECT Corporation earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 47.3648921199679 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
A number of brokerages have recently issued reports on DRRX. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of DURECT Corporation in a report on Monday, May 22nd. Stifel Nicolaus raised DURECT Corporation from a “hold” rating to a “buy” rating and increased their target price for the stock from $1.25 to $3.00 in a report on Wednesday, July 12th.
DURECT Corporation (DRRX) traded up 0.62% during midday trading on Friday, reaching $1.61. The company had a trading volume of 681,395 shares. The stock’s market cap is $236.67 million. The firm has a 50-day moving average of $1.64 and a 200-day moving average of $1.31. DURECT Corporation has a 12 month low of $0.74 and a 12 month high of $1.90.
DURECT Corporation (NASDAQ:DRRX) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). DURECT Corporation had a negative net margin of 221.01% and a negative return on equity of 629.35%. The company had revenue of $4.32 million during the quarter, compared to the consensus estimate of $5.17 million. On average, equities analysts expect that DURECT Corporation will post ($0.21) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was reported by BBNS and is the property of of BBNS. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://baseballnewssource.com/markets/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-durect-corporation-drrx-stock-price/1566529.html.
About DURECT Corporation
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with our FREE daily email newsletter.